RxSight Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $33.7 million for Q2 2026, including $6.5 million from the Alcon collaboration.

Product Sales: $27.2 million, a 19% decrease year-over-year, attributed to competitive trialing and broader market headwinds.

LAL Unit Volume: 24,917 units sold, down 9% from the previous year.

Gross Margin: 71.2%, down from 74.9% year-over-year, primarily due to increased inventory costs.

Net Loss: $12.1 million, or $0.29 per share; adjusted net loss was $4.6 million, or $0.11 per share.

Cash Position: Approximately $209 million at quarter-end, excluding a $60 million payment received post-quarter from the Alcon partnership.

2Strategic Updates and Business Highlights

Leadership Change: Aziz Mottiwala has joined as CEO, emphasizing the importance of differentiated innovation and customer engagement.

Alcon Collaboration: A significant milestone providing $200 million in upfront and potential future milestone payments, along with long-term royalties, validating the technology's potential.

Market Positioning: RxSight aims to enhance the adoption of its adjustable IOL technology, focusing on improving physician workflows and patient outcomes.

Sales Strategy: Plans to double the U.S. sales team over time to increase market penetration and support existing customers.

3Forward Guidance and Outlook

Withdrawal of Guidance: The company has withdrawn its full-year 2026 financial guidance to allow for a thorough business assessment, with plans to provide new guidance in early 2027.

Revenue Expectations: Anticipates recognizing $30 million to $40 million from the Alcon agreement, with variable timing for revenue recognition.

4Bad News, Challenges, or Points of Concern

Declining Product Sales: A notable 19% decrease in product sales year-over-year, indicating challenges in market adoption and competitive pressures.

Utilization Issues: Despite strong physician confidence in the technology, there is a need to improve procedure volume and utilization.

Market Headwinds: Ongoing competitive activity and broader market trends are expected to impact performance in the near term.

Operational Challenges: The company faces challenges in integrating the light adjustable lens into existing workflows and identifying ideal patient candidates.

5Notable Q&A Insights

CEO's Vision: Mottiwala expressed confidence in the technology's potential and the need for a strategic pivot from broad user base establishment to deeper engagement and utilization.

Physician Feedback: Surgeons are eager to use more LALs but require support in optimizing workflows and identifying suitable patients.

Future KPIs: The focus will be on increasing the number of LAL procedures and refining KPIs to align with business goals.

Market Trends: Mottiwala highlighted the increasing demand for perfect vision among patients, suggesting a shift in physician focus towards technologies that deliver exceptional outcomes. Overall, RxSight is navigating a challenging market environment while laying the groundwork for a strategic reassessment aimed at enhancing growth and adoption of its innovative cataract surgery technology.